{"id":"nucleoside-reverse-transcriptase-inhibitors","safety":{"commonSideEffects":[{"rate":null,"effect":"Mitochondrial toxicity / lactic acidosis"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs are nucleoside analogs that compete with natural nucleosides for incorporation into the growing DNA chain during reverse transcription. Once incorporated, they cause chain termination because they lack a 3'-OH group needed for the next phosphodiester bond. This prevents HIV from converting its RNA genome into DNA, which is essential for the virus to integrate into the host cell genome and replicate.","oneSentence":"Nucleoside reverse transcriptase inhibitors block the reverse transcriptase enzyme that HIV uses to convert its RNA genome into DNA, preventing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:56.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT05330923","phase":"","title":"Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-05-01","conditions":"Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis","enrollment":200},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07210528","phase":"PHASE1","title":"Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-06-30","conditions":"Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)","enrollment":48},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT02363452","phase":"PHASE2","title":"Reverse Transcriptase Inhibitors in AGS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-10","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":11},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04500847","phase":"PHASE1","title":"Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD","status":"RECRUITING","sponsor":"Butler Hospital","startDate":"2021-12-17","conditions":"Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia","enrollment":35},{"nctId":"NCT03304717","phase":"PHASE1, PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":"Aicardi Goutières Syndrome","enrollment":""},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT01327651","phase":"PHASE2","title":"The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2011-08","conditions":"HIV Infections","enrollment":622},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT06704204","phase":"","title":"Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community","status":"NOT_YET_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2025-02","conditions":"HIV","enrollment":20},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT05300035","phase":"PHASE2","title":"Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-11","conditions":"HIV/AIDS and Infections","enrollment":69},{"nctId":"NCT05349838","phase":"PHASE3","title":"Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2018-11-05","conditions":"HIV-1-infection","enrollment":140},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT05699759","phase":"PHASE1","title":"Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema","status":"COMPLETED","sponsor":"Michelle Abou-Jaoude","startDate":"2024-01-04","conditions":"Diabetic Macular Edema","enrollment":1},{"nctId":"NCT05734807","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia","status":"COMPLETED","sponsor":"Huahui Health","startDate":"2022-07-20","conditions":"Chronic HBV Infection","enrollment":74},{"nctId":"NCT06609941","phase":"NA","title":"Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma","status":"RECRUITING","sponsor":"Foundation University Islamabad","startDate":"2024-06-18","conditions":"Bronchial Asthma","enrollment":32},{"nctId":"NCT03894124","phase":"PHASE1","title":"Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2019-06-12","conditions":"Human Immunodeficiency Virus","enrollment":24},{"nctId":"NCT04133012","phase":"NA","title":"Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-02-10","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT02429791","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-14","conditions":"HIV Infections","enrollment":510},{"nctId":"NCT02422797","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-21","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT06566248","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-20","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT06485154","phase":"PHASE4","title":"Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2024-06-01","conditions":"HIV Prevention","enrollment":100},{"nctId":"NCT04493216","phase":"PHASE2","title":"A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2020-11-18","conditions":"HIV Infections","enrollment":161},{"nctId":"NCT00799864","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-01","conditions":"HIV-1","enrollment":54},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT06452693","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-06","conditions":"Hepatitis B, Chronic","enrollment":162},{"nctId":"NCT04731103","phase":"PHASE2","title":"Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-08-24","conditions":"Aicardi-Goutières Syndrome","enrollment":13},{"nctId":"NCT06356740","phase":"PHASE2","title":"Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT03493568","phase":"PHASE3","title":"Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)","status":"TERMINATED","sponsor":"IRCCS San Raffaele","startDate":"2017-02-06","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT02437110","phase":"PHASE1","title":"HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-04-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":122},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT01671982","phase":"PHASE1","title":"ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2012-08","conditions":"HIV","enrollment":40},{"nctId":"NCT04892654","phase":"PHASE3","title":"Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch","status":"RECRUITING","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-08-17","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT04066036","phase":"","title":"Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-14","conditions":"HIV-1-infection","enrollment":1000},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT03780543","phase":"PHASE2","title":"A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2018-12-20","conditions":"Chronic Hepatitis B","enrollment":92},{"nctId":"NCT04194021","phase":"","title":"Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir","status":"UNKNOWN","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2019-01-01","conditions":"HIV/AIDS","enrollment":871},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05682599","phase":"PHASE2","title":"Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-01-06","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05633433","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-12-29","conditions":"SARS-CoV-2 Infection","enrollment":1550},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT02010593","phase":"PHASE2","title":"Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women","status":"COMPLETED","sponsor":"International Partnership for Microbicides, Inc.","startDate":"2013-12","conditions":"Human Immunodeficiency Virus","enrollment":96},{"nctId":"NCT05536466","phase":"NA","title":"The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-09-30","conditions":"HIV Infections, Bariatric Surgery Candidate","enrollment":8},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT04551261","phase":"PHASE1","title":"GLS4/RTV and TAF Drug-drug Interaction","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-10","conditions":"Chronic Hepatitis B","enrollment":28},{"nctId":"NCT03782142","phase":"","title":"Effect on HIV Medications on EPC Cells","status":"COMPLETED","sponsor":"Sabyasachi Sen","startDate":"2018-11-01","conditions":"AIDS","enrollment":22},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00006396","phase":"PHASE3","title":"Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT00000872","phase":"PHASE2","title":"Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00001091","phase":"PHASE1","title":"Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00001084","phase":"PHASE2","title":"A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00001085","phase":"PHASE2","title":"A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00001095","phase":"PHASE2","title":"A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00110812","phase":"PHASE2","title":"Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"HIV Infections","enrollment":267},{"nctId":"NCT00017719","phase":"PHASE3","title":"Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-05","conditions":"HIV Infections, Pregnancy","enrollment":440},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00028366","phase":"NA","title":"Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00001086","phase":"PHASE2","title":"A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00008866","phase":"PHASE2","title":"Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00036452","phase":"PHASE2","title":"A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":402},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT00006144","phase":"PHASE2","title":"A Study of HIV-Disease Development in Aging","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-10","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00000822","phase":"PHASE1","title":"A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00000916","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":399},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3751,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nucleoside reverse transcriptase inhibitors","genericName":"nucleoside reverse transcriptase inhibitors","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nucleoside reverse transcriptase inhibitors block the reverse transcriptase enzyme that HIV uses to convert its RNA genome into DNA, preventing viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}